新型冠状病毒肺炎淋巴细胞亚群与严重程度的相关分析

doi:10.19723/j.issn.1671-167X.2020.06.014

摘要/Abstract

摘要：

目的:了解不同临床亚型新型冠状病毒肺炎(corona virus disease 19, COVID-19)患者淋巴细胞亚群的差异。方法:选取2020年2月8日至3月28日在华中科技大学同济医学院附属同济医院中法新城院区由三家援鄂医疗队负责的隔离病房收治的81例COVID-19患者为研究对象。根据相关诊断标准,将患者的疾病状态分为普通型(35例)、重型(39例)、危重型(7例)。检测血常规、淋巴细胞亚群等指标,比较不同临床亚型组患者间各指标是否存在差异。结果:三组患者淋巴细胞、T淋巴细胞、CD4⁺T淋巴细胞、CD8⁺T淋巴细胞、自然杀伤(natural killer,NK)细胞绝对数等指标差异均有统计学意义(P<0.05),危重型患者上述指标均明显低于普通型及重型患者,且随疾病严重程度加重呈递减趋势。22例患者首次检测时T淋巴细胞、B淋巴细胞、CD4⁺T淋巴细胞、CD8⁺T淋巴细胞及NK细胞绝对数、CD4⁺/CD8⁺六项指标均在正常参考值范围内,59例患者上述指标存在异常,以NK细胞和CD8⁺T淋巴细胞绝对数减少最为常见(61%,56%)。将NK、CD8⁺T淋巴细胞绝对数均低于正常参考值范围患者作为一组,其余指标异常患者作为一组,前者危重型患者较多(普通型:重型:危重型分别为4:8:7 vs. 19:21:0,P=0.001),且死亡病例均在此组(6例 vs. 0例,P=0.001)。15例患者B淋巴细胞绝对数低于正常参考值范围,余64例均在正常参考值范围内,减低组与正常组普通型:重型:危重型分别为4:7:4和30:31:3,减低组危重型患者比例多于正常组,两组间差异有统计学意义(P=0.043)。结论:COVID-19患者临床亚型越危重淋巴细胞各亚群绝对数越低。

关键词: 冠状病毒感染, 肺炎, 病毒性, 淋巴细胞亚群

Abstract:

Objective: To understand the differences in lymphocyte subsets in patients with different clinical classifications of corona virus disease 19 (COVID-19). Methods: Eighty-one patients with COVID-19 who were admitted to the isolation ward under the responsibility of three medical aid teams in the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, from February 8, 2020 to March 28, 2020, were selected to collect clinical data. According to the relevant diagnostic criteria, the disease status of the patients was classified into moderate cases (n=35), severe cases (n=39) and critical cases (n=7) when lymphocyte subset testing was performed. Their blood routine tests, lymphocyte subsets and other indicators were tested to compare whether there were differences in each indicator between the patients of different clinical classification groups. Results: The differences in the absolute count of total lymphocytes, T-lymphocytes, CD4⁺T-lymphocytes, CD8⁺T-lymphocytes and natural killer (NK) cells among the three groups of patients were all statistically significant (P<0.05), and the critical cases were significantly lower than the moderate and severe cases in the above indicators, and the indicators showed a decreasing trend with the severity of the disease. In 22 patients, the six indicators of the absolute count of T-lymphocytes, B-lymphocytes, CD4⁺T-lymphocytes, CD8⁺T-lymphocytes and NK cells, CD4⁺/CD8⁺ ratio were all within the normal reference range in the first test, and 59 patients had abnormalities of the above indicators, with the absolute count of NK cells and CD8⁺ T lymphocytes decreasing most frequently (61%, 56%). The patients with the absolute count of NK cells and CD8⁺ T lymphocytes below the normal reference range were one group, and the remaining abnormal patients were the other group. There were more critical cases in the former group (moderate:severe:critical cases were 4:8:7 vs. 19:21:0, respectively, P=0.001), and all the deaths were in this group (6 cases vs. 0 case, P=0.001). The absolute B lymphocyte count was below the normal reference range in 15 patients, and the remaining 64 cases were within the normal range. The ratio of moderate, severe and critical cases in the reduced group was 4:7:4, and the ratio of critical cases was more in normal group which was 30:31:3, and the difference between the two groups was statistically significant (P=0.043). Conclusion: The more critical the clinical subtype of patients with COVID-19, the lower the absolute count of each subset of lymphocytes.

Key words: Coronavirus infections, Pneumonia, viral, Lymphocyte subsets

中图分类号:

R563.12

包芳,史尉利,胡静,张娣,高东晗,夏云霞,景红梅,克晓燕,葛庆岗,沈宁. 新型冠状病毒肺炎淋巴细胞亚群与严重程度的相关分析[J]. 北京大学学报（医学版）, 2020, 52(6): 1075-1081.

Fang BAO,Wei-li SHI,Jing HU,Di ZHANG,Dong-han GAO,Yun-xia XIA,Hong-mei JING,Xiao-yan KE,Qing-gang GE,Ning SHEN. Analysis of the correlation between lymphocyte subsets and severity of corona virus disease 19[J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1075-1081.

图/表 8

表1

不同临床亚型患者基本资料"

Characteristic	Moderate (n=35)	Severe (n=39)	Critical (n=7)	P value
Male:Female	18:17	17:22	4:3	0.856
Age/years, M (P₂₅, P₇₅)	58 (44, 63)	68 (58, 73)^*	62 (59, 75)	0.001
Diabetes, n	7	20	4	0.010
Hypertension, n	10	22	2	0.038
Diabetes + Hypertension, n	3	10	0	0.039
Time from onset to test/d, $x -$ ±s	36.3±10.0	31.6±8.3	34.3±19.1	0.136

表1

表2

表3

首次检测淋巴细胞亚群正常组及异常组基本资料"

Characteristic	Normal (n=22)	Abnormal (n=59)	P
Male:Female	12:10	27:32	0.618
Age/years, $x -$ ±s	52.3±13.3	62.7±12.6	0.002
Clinical classifications (Moderate:Severe:Critical)	12:10:0	23:29:7	0.069
Time from onset to test/d, $x -$ ±s	35.1±9.7	33.4±10.7	0.431
Deaths, n	0	6	0.271

表3

表4

首次检测时淋巴细胞亚群计数处于正常范围患者基本资料"

Characteristic	Moderate (n=12)	Severe (n=10)	P
Male:Female	8:4	4:6	0.412
Age/years, $x -$ ±s	49.0±12.1	56.2±14.3	0.107
Time from onset to test/d, $x -$ ±s	37.8±10.8	31.8±7.5	0.228

表4

表5

表6

NK细胞、CD8+ T淋巴细胞低于正常参考值范围组与其他指标异常组患者比较"

Items	NK & CD8⁺ T cell both decrease (n=19)	Other index anomaly (n=40)	P
Males:Females	8:11	19:21	0.698
Age/years, $x -$ ±s	67.1±11.1	60.6±13.0	0.063
Clinical classifications (Moderate:Severe:Critical)	4:8:7	19:21:0	0.001
Time from onset to test/d, $x -$ ±s	32.6±13.5	33.8±9.2	0.526
Deaths, n	6	0	0.001

表6

表7

B淋巴细胞计数减低组与正常组比较"

Items	B-lymphocyte decrease (n=15)	B-lymphocyte normal (n=64)	P
Males:Females	8:7	30:34	0.652
Age/years, $x -$ ±s	63.5±10.9	59.5±13.7	0.381
Clinical classifications (Moderate:Severe:Critical)	4:7:4	30:31:3	0.043

表7

表8

参考文献 14

[1]	Luo Y, Xie YL, Zhang WJ, et al. Combination of lymphocyte number and function in evaluating host immunity[J]. Aging (Albany NY), 2019,11(24):12685-12707.
[2]	Qin C, Zhou LQ, Hu ZW, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China[J]. Clin Infect Dis, 2020,71(15):762-768. pmid: 32161940
[3]	Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020,579(7798):270-273. doi: 10.1038/s41586-020-2012-7 pmid: 32015507
[4]	Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020,323(11):1061-1069. doi: 10.1001/jama.2020.1585 pmid: 32031570
[5]	Tan L, Wang Q, Zhang DY, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study[J]. Signal Transduct Target Ther, 2020,5(1):33. pmid: 32296069
[6]	董庆鸣, 何忠平, 庄辉, 等. SARS患者外周血B淋巴细胞和自然杀伤细胞动态变化[J]. 中华流行病学杂志, 2004,25(8):695-697.
[7]	He ZP, Zhao CH, Dong QM, et al. Effects of severe acute respi-ratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets[J]. Int J Infect Dis, 2005,9(6):323-330. pmid: 16095942
[8]	Chen MH, Wong VW, Wong CK, et al. Serum LD1 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute respiratory syndrome[J]. J Inter Med, 2004,255(4):512-518.
[9]	贺莉, 丁彦青, 王蔚, 等. 免疫细胞在SARS病变组织中的表达及其作用[J]. 第一军医大学学报, 2003,23(8):774-776, 780.
[10]	Glass WG, Subbarao K, Murphy B, et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice[J]. J Immunol, 2004,173(6):4030-4039. pmid: 15356152
[11]	Maloir Q, Ghysen K, von Frenckell C, et al. Détresse respiratoire aiguё révélatrice d’un syndrome des antisynthétases[J]. Rev Med Liege, 2018,73(7-8):370-375. pmid: 30113776
[12]	Chen J, Lau YF, Lamirande E W, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4⁺ T cells are important in control of SARS-CoV infection[J]. J Virol, 2010,84(3):1289-1301. pmid: 19906920
[13]	Wang F, Nie JY, Wang HZ, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia[J]. J Infect Dis, 2020,221(11):1762-1769. pmid: 32227123
[14]	Zhang Z, Xu DP, Li YG, et al. Longitudinal alteration of circulating dendritic cell subsets and its correlation with steroid treatment in patients with severe acute respiratory syndrome[J]. Clin Immunol, 2005,116(3):225-235. doi: 10.1016/j.clim.2005.04.015 pmid: 15964242

相关文章 15

[1]	李佳,徐钰,王优雅,高占成. 老年流感肺炎的临床特征及D-二聚体与疾病严重程度的相关性[J]. 北京大学学报（医学版）, 2022, 54(1): 153-160.
[2]	王飞,朱翔,贺蓓,朱红,沈宁. 自发缓解的滤泡性细支气管炎伴非特异性间质性肺炎1例报道并文献复习[J]. 北京大学学报（医学版）, 2021, 53(6): 1196-1200.
[3]	黄冰, 王洪源. 全球新型冠状病毒肺炎疫情发展趋势及严重程度[J]. 北京大学学报（医学版）, 2021, 53(3): 536-542.
[4]	杨群智,张舸,费雅楠,付爽,闫冰. 沙利度胺治疗原发性干燥综合征合并轻中度非特异性间质性肺炎疗效观察[J]. 北京大学学报（医学版）, 2021, 53(2): 413-416.
[5]	袁晓宁,孟庆阳,沈宁,李宇轩,梁超,崔曼,葛庆岗,李晓光,谭昆,陈茜,王晶,曾晓勇. 新型冠状病毒肺炎病区环境及医务人员防护设备表面SARS-CoV-2核酸污染的检测与评价[J]. 北京大学学报（医学版）, 2020, 52(5): 803-808.
[6]	李秋钰,程秦,赵志伶,代妮妮,曾琳,朱兰,郭炜,李超,王军红,李姝,葛庆岗,沈宁. 肾移植术后感染新型冠状病毒1例[J]. 北京大学学报（医学版）, 2020, 52(4): 780-784.
[7]	王秋,郭金玉,孙红,王泠,应菊素,刘慧鑫. 抗击新型冠状病毒肺炎一线护理人员防护暴露风险事件调查[J]. 北京大学学报（医学版）, 2020, 52(4): 711-714.
[8]	邢燕,张娟,韩彤妍,李在玲,李蕊,童笑梅. 新型冠状病毒感染肺炎疫情下综合医院儿科防控方式探索[J]. 北京大学学报（医学版）, 2020, 52(3): 410-413.
[9]	杨航,杨林承,张瑞涛,凌云鹏,葛庆岗. 合并高血压、冠心病、糖尿病的新型冠状病毒肺炎患者发生病死的危险因素分析[J]. 北京大学学报（医学版）, 2020, 52(3): 420-424.
[10]	陈美恋,高燕,郭维,左力,王天兵. 新型冠状病毒肺炎患者床旁血液净化治疗的感染防控[J]. 北京大学学报（医学版）, 2020, 52(3): 414-419.
[11]	杜建,詹启敏. 后疫情时代促进我国医学发展的思考与建议[J]. 北京大学学报（医学版）, 2020, 52(3): 405-409.
[12]	北京大学肿瘤医院新型冠状病毒疫情防控领导小组,季加孚. 北京大学肿瘤医院关于新型冠状病毒疫情期间肿瘤诊治的建议[J]. 北京大学学报（医学版）, 2020, 52(2): 199-203.
[13]	冯文,张靓囡,李璟媛,魏田,彭婷婷,张东旭,郭在新,王伟嵩. 基于互联网的新型冠状病毒肺炎健康咨询服务分析[J]. 北京大学学报（医学版）, 2020, 52(2): 302-307.
[14]	路明,闫葳,朱翔,朱红. 长期应用复方薄荷脑滴鼻液导致外源性脂质性肺炎1例[J]. 北京大学学报（医学版）, 2019, 51(2): 359-361.
[15]	吴小静，李敏，詹庆元. 以高热为表现的外源性脂质性肺炎1例[J]. 北京大学学报(医学版), 2018, 50(5): 921-923.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Characteristic	Moderate (n=35)	Severe (n=39)	Critical (n=7)	P
Leukocyte/(×10⁹/L)	5.69±1.51	5.75±1.53	12.18±2.76	<0.001
Neutrophil/%	54.56±7.07	60.22±8.38	90.73±4.19	<0.001
Neutrophil/(×10⁹/L)	2.95 (2.35, 3.51)	3.36 (2.91, 3.66)	11.49 (9.67, 12.72)	<0.001
Lymphocyte/%	32.51±6.64	27.04±7.65	4.74±3.09	<0.001
Lymphocyte/(×10⁹/L)	1.82±0.51	1.52±0.50	0.52±0.19	<0.001
Monocyte/%	9.38±2.14	9.35±2.06	3.87±1.32	<0.001
Monocyte/(×10⁹/L)	0.53±0.16	0.54±0.20	0.46±0.17	0.693
Eosinophil/%	2.8 (1.9, 3.9)	2.1 (1.5, 3.2)	0.1 (0.05, 0.75)	<0.001
Eosinophil/(×10⁹/L)	0.17±0.11	0.17±0.17	0.05±0.06	0.010
Basophil/%	0.51±0.25	0.52±0.36	0.21±0.23	0.018
Basophil/(×10⁹/L)	0.03 (0.02, 0.04)	0.03 (0.01, 0.04)	0.01 (0.01, 0.02)	0.173
CD3⁺CD19^-T-cell/%	74.00±7.03	73.72±10.14	64.84±14.87	0.125
CD3⁺CD19^-T-cell/(cells/μL)	1 292±395	1 094±408	295±156	<0.001
CD3^-CD19⁺B-cell/%	12.27±4.96	12.64±7.05	23.77±18.78	0.055
CD3^-CD19⁺B-cell/(cells/μL)	225±126	180±101	110±91	0.033
CD4⁺T-cell/%	47.61±7.89	45.56±7.70	44.66±16.01	0.501
CD4⁺T-cell/(cells/μL)	838±304	675±260	212±145	<0.001
CD8⁺T-cell/%	23.08±6.06	25.73±9.69	18.86±11.80	0.216
CD8⁺T-cell/(cells/μL)	410±135	383±198	77±39	<0.001
CD3^-/CD16⁺CD56⁺NK cell/%	12.99±6.85	12.95±6.24	10.13±8.54	0.584
CD3^-/CD16⁺CD56⁺NK cell/(cells/μL)	212±106	185±101	39±28	<0.001
T⁺B⁺NK cell/%	99.25±0.52	99.33±0.51	98.74±0.95	0.054
T⁺B⁺NK cell/(cells/μL)	1 729±464	1 435±505	444±182	<0.001
CD4⁺/CD8⁺	2.14±0.76	2.08±1.07	3.35±1.97	0.242

Items	Below normal range	In normal range	Above normal range
CD3⁺CD19^-T-cell	27 (46)	32 (54)	0
CD3^-CD19⁺B-cell	15 (25)	42 (71)	2 (3)
CD3^-/CD16⁺CD56⁺NK cell	36 (61)	23 (39)	0
CD4⁺T-cell	24 (41)	34 (58)	1 (2)
CD8⁺T-cell	33 (56)	26 (44)	0
CD4⁺/CD8⁺	1 (2)	41 (69)	17 (29)

Items	B-lymphocyte decrease (n=5)	B-lymphocyte normal (n=33)	P
Time from onset to test/d, M(P₂₅, P₇₅)	45.0 (28.5, 51.0)	39.0 (32.0, 43.0)	0.585
IgM/(AU/mL), M(P₂₅, P₇₅)	59.47 (42.79, 76.05)	39.42 (14.29, 106.21)	0.449
IgG/(AU/mL), M(P₂₅, P₇₅)	209.03 (92.91, 329.47)	173.70 (149.15, 207.09)	0.645